Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Invested Capital: 2013-2025

Historic Invested Capital for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $87.8 million.

  • Coherus Oncology's Invested Capital rose 211.43% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 211.43%. This contributed to the annual value of -$118.4 million for FY2024, which is 37.74% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Invested Capital is $87.8 million, which was down 26.75% from $119.8 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Invested Capital ranged from a high of $386.2 million in Q2 2021 and a low of -$196.3 million during Q1 2023.
  • For the 3-year period, Coherus Oncology's Invested Capital averaged around -$90.4 million, with its median value being -$118.4 million (2024).
  • As far as peak fluctuations go, Coherus Oncology's Invested Capital plummeted by 1,662.84% in 2023, and later surged by 259.97% in 2025.
  • Coherus Oncology's Invested Capital (Quarterly) stood at $97.7 million in 2021, then tumbled by 240.62% to -$137.4 million in 2022, then slumped by 38.36% to -$190.1 million in 2023, then surged by 37.74% to -$118.4 million in 2024, then surged by 211.43% to $87.8 million in 2025.
  • Its Invested Capital stands at $87.8 million for Q3 2025, versus $119.8 million for Q2 2025 and -$157.2 million for Q1 2025.